Haemonetics (NYSE:HAE) this week appointed James D’Arecca as chief financial officer, effective on April 11.
D’Arecca will oversee the company’s treasury, controllership and accounting, investor relations, tax, information technology and financial planning and analysis functions. He will report directly to president and CEO Chris Simon. He succeeds William Burke who will remain with Haemonetics in an advisory role through June 30.
“Haemonetics is recognized and respected for its long history of innovation and industry leadership in improving standards of care. I am excited to help the Company continue to achieve strong results, accelerate growth, and expand its impact throughout the world,” D’Arecca said in a news release.
Prior to joining the company, D’Arecca was the chief financial officer of TherapeuticsMD. He previously served as senior VP and chief accounting officer at Allergan and held leadership roles at Bausch + Lomb, Merck and Schering-Plough.
“James brings to Haemonetics substantial experience in financial leadership for prominent global healthcare organizations,” said Simon. “His expertise will play a significant role in supporting our Company’s transformational growth objectives and delivering long-term value for our stakeholders. We are excited to welcome him to Haemonetics to lead our global Finance team.”